HDM1002
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Huadong Medicine · Phase 1 · Status n/r · Enrollment 30
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| HDM1002 with Repaglinide, Atorvastatin, Digoxin and Rosuvastatin | Obesity or overweight | n/r | n/r | n/r | n/r |